CEO Corner

  1. Lessons Learned: The Start Of mRNA Technology Development 2/1/2019

    Can German, American, Chinese, and other companies worldwide work together to advance the mRNA revolution and possibly launch the new “pharmacy of the world?”

  2. Turning The Ocean Liner: How To Advocate For A Breakthrough Treatment Paradigm 1/2/2019

    Like an ocean liner changing course, the national discussion around “modern” healthcare has moved slowly away from volume toward health outcomes. As such, we in the industry need to be both innovators and advocates for change.

  3. CEO Corner: On Leadership 10/4/2018

    “I’m often asked what it takes to be a successful biotech CEO, and as one of the relatively few female CEOs in our industry, what it takes to break the proverbial glass ceiling.”

  4. My Life As A Recovering VC, Zigging Where Others Zag 9/3/2018

    Identifying and acquiring medicines would be relatively facile; however, convincing investors that the medicines were valuable was going to be a real challenge.

  5. Key Considerations For Building A Fully Integrated Biopharmaceutical Company 8/2/2018

    There are some key points for biotech companies to consider as they begin to transform their business model to one that captures the business continuum more fully.

  6. Patients And Biopharma: Trusted Partners In Fighting Rare Diseases 7/5/2018

    Partnerships between pharmaceutical companies and patient advocacy groups hold the key to closing the rare-disease treatment gap. Their mutual commitment to improving patient care is the foundation for collaborative innovation in rare-disease education and research.

  7. Building A Biotech with A Diversity Mindset 6/1/2018

    A diverse workplace is critical to building a successful biotech company. When you’re leading an organization working to bring life-saving drugs to the market, every second matters, and you need to attract and retain the best talent to be successful.

  8. Leaders In Biotech: Raising Our Voices Beyond Industry's Walls 5/2/2018

    The CEO of Ovid Therapeutics, Jeremy Levin, feels no time has ever been better for biopharma leaders to speak out as part of their commitment to this industry.

  9. What Drug Developers Can Learn From Silicon Valley 2/7/2018

    Though biotechnology may never be as fast and efficient as software, we can make innovation and development faster — through nothing more than a Silicon-Valley way of thinking.

  10. The Emergence Of New Gene Therapy Hubs 1/9/2018

    With gene therapy, we are at the dawn of another era of potentially rapid growth in the sector. And companies planning for their futures will once again consider a range of factors in identifying the optimal locations for gene therapy research and production centers.